{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:03:31Z","timestamp":1778605411943,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023-00207920"],"award-info":[{"award-number":["RS-2023-00207920"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2031185"],"award-info":[{"award-number":["2020R1A5A2031185"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["2710086664\/RS-2025-02223662"],"award-info":[{"award-number":["2710086664\/RS-2025-02223662"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.tranon.2025.102475","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T21:18:35Z","timestamp":1753391915000},"page":"102475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells"],"prefix":"10.1016","volume":"60","author":[{"given":"Seo-Yeon","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manh-Cuong","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van-Tan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1285-1184","authenticated-orcid":false,"given":"Van-Dinh-Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Nguyen","family":"Duc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102475_bib0001","unstructured":"Clinic, M. (n.d.). Multiple myeloma. Mayo Clinic. Retrieved July 18, 2025, from https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-myeloma\/symptoms-causes\/syc-20353378."},{"issue":"14","key":"10.1016\/j.tranon.2025.102475_bib0002","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Zaoqu Liu","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.tranon.2025.102475_bib0003","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Vladimir Jurisic","year":"2007","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2025.102475_bib0004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.tranon.2025.102475_bib0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","article-title":"Treatment of multiple myeloma: a comprehensive review","volume":"9","author":"Kyle RA","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"9","key":"10.1016\/j.tranon.2025.102475_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091506","article-title":"Development of novel immunotherapies for multiple myeloma","volume":"17","author":"Al-Hujaily","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.tranon.2025.102475_bib0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/OP.21.00032","article-title":"Immunotherapy in multiple myeloma-time for a second major paradigm shift","volume":"17","author":"Mohan","year":"2021","journal-title":"JCo Oncol. Pr."},{"issue":"9","key":"10.1016\/j.tranon.2025.102475_bib0008","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201545552","article-title":"Adoptive T-cell therapy for cancer: the era of engineered T cells","volume":"45","author":"Bonini","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.tranon.2025.102475_bib0009","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni1249","article-title":"Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells","volume":"6","author":"Cavanagh","year":"2005","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.tranon.2025.102475_bib0010","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","article-title":"Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells","volume":"70","author":"Bernal","year":"2009","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102475_bib0011","article-title":"Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: coupling active strategies to overcome therapeutic limitations","volume":"70","author":"Wang","year":"2022","journal-title":"Curr. Res. Transl. Med."},{"issue":"22","key":"10.1016\/j.tranon.2025.102475_bib0012","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Rafet Br","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.tranon.2025.102475_bib0013","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.tranon.2025.102475_bib0014","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.tranon.2025.102475_bib0015","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Matteo","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2025.102475_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.01.013","article-title":"Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone?","volume":"343","author":"Badalamenti","year":"2019","journal-title":"Cell Immunol."},{"key":"10.1016\/j.tranon.2025.102475_bib0017","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Fatjona","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102475_bib0018","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PPO.0000000000000159","article-title":"Marrow infiltrating lymphocytes: their role in adoptive immunotherapy","volume":"21","author":"Kimberly AN","year":"2015","journal-title":"Cancer J."},{"issue":"62","key":"10.1016\/j.tranon.2025.102475_bib0019","doi-asserted-by":"crossref","first-page":"32024","DOI":"10.18632\/oncotarget.25882","article-title":"PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients","volume":"9","author":"Sponaas","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.tranon.2025.102475_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2005.01.008","article-title":"Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells","volume":"22","author":"Mazo","year":"2005","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.tranon.2025.102475_bib0021","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat. Med."},{"issue":"288","key":"10.1016\/j.tranon.2025.102475_bib0022","first-page":"288ra78","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Kimberly","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.tranon.2025.102475_bib0023","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.leukres.2007.01.012","article-title":"Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome","volume":"31","author":"Gordana Bogdanovi\u0107","year":"2007","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.tranon.2025.102475_bib0024","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2003-01-0183","article-title":"IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro","volume":"102","author":"Nuno L Alves","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tranon.2025.102475_bib0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Nicoletta Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102475_bib0026","article-title":"Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma","author":"Gordana Konjevi\u0107","year":"2016","journal-title":"J. Clin. Pathol."},{"issue":"11","key":"10.1016\/j.tranon.2025.102475_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026908","article-title":"A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time","volume":"6","author":"Smith","year":"2011","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2025.102475_bib0028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-94-017-7215-0_8","article-title":"Konjevic the actual role of LDH as tumor marker, biochemical and clinical aspects","volume":"867","author":"Jurisic","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tranon.2025.102475_bib0029","article-title":"Interleukin-4-induced natural killer cell antitumor activity in metastatic melanoma patients","author":"Ana M Vuleti\u0107","year":"2020","journal-title":"Eur. Cytokine Netw."},{"issue":"8","key":"10.1016\/j.tranon.2025.102475_bib0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2025.102475_bib0031","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102475_bib0032","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2025.102475_bib0033","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.tranon.2025.102475_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends. Immunol."},{"issue":"10","key":"10.1016\/j.tranon.2025.102475_bib0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102475_bib0036","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/cells11030410","article-title":"Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells: response and resistance","volume":"11","author":"Franziska F\u00fcchsl","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.tranon.2025.102475_bib0037","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Jr., Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.tranon.2025.102475_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745109","article-title":"A correlation between differentiation phenotypes of infused T cells and anti-cancer immunotherapy","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2025.102475_bib0039","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102475_bib0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J. Clin. Invest."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:51:53Z","timestamp":1772765513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325002062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"alternative-id":["S1936523325002062"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102475","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102475"}}